相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advances in the Pharmacogenomics of Adverse Drug Reactions
Susannah L. Collins et al.
DRUG SAFETY (2016)
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib
C. F. Spraggs et al.
ANNALS OF ONCOLOGY (2015)
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
C-F Xu et al.
BRITISH JOURNAL OF CANCER (2015)
High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation
Tatiana V. Gorodnova et al.
CANCER LETTERS (2015)
Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics
Pasi Soininen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Predicting drug metabolism: experiment and/or computation?
Johannes Kirchmair et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Pharmacogenomic information in drug labels: European Medicines Agency perspective
F. Ehmann et al.
PHARMACOGENOMICS JOURNAL (2015)
Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics
Pasi Soininen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
M. A. Province et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Characterization of Statin Dose Response in Electronic Medical Records
W-Q Wei et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia Reply
S. Tiong Ong et al.
NATURE MEDICINE (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Danielle Welter et al.
NUCLEIC ACIDS RESEARCH (2014)
A Bayesian Method to Incorporate Hundreds of Functional Characteristics with Association Evidence to Improve Variant Prioritization
Sarah A. Gagliano et al.
PLOS ONE (2014)
Genomic architecture of pharmacological efficacy and adverse events
Aparna Chhibber et al.
PHARMACOGENOMICS (2014)
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
F. Aminkeng et al.
PHARMACOGENOMICS JOURNAL (2014)
The pharmacogenomics of statins
Ingrid C. Gelissen et al.
PHARMACOLOGICAL RESEARCH (2014)
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
Iris Postmus et al.
NATURE COMMUNICATIONS (2014)
Integrating Functional Data to Prioritize Causal Variants in Statistical Fine-Mapping Studies
Gleb Kichaev et al.
PLOS GENETICS (2014)
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
Paul Geeleher et al.
GENOME BIOLOGY (2014)
An investigation of the false discovery rate and the misinterpretation of p-values
David Colquhoun
ROYAL SOCIETY OPEN SCIENCE (2014)
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
Maria Frantzi et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2014)
To Replicate or Not to Replicate: The Case of Pharmacogenetic Studies Have Pharmacogenomics Failed, or Do They Just Need Larger-Scale Evidence and More Replication?
John P. A. Ioannidis
CIRCULATION-CARDIOVASCULAR GENETICS (2013)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
Minoli A. Perera et al.
LANCET (2013)
Validating therapeutic targets through human genetics
Robert M. Plenge et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Pharmacogenetics and Coumarin Dosing - Recalibrating Expectations
Issam Zineh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Munir Pirmohamed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment
Louise A. Donnelly et al.
PHARMACOGENETICS AND GENOMICS (2013)
Towards the identification of imaging biomarkers in schizophrenia, using multivariate pattern classification at a single-subject level
Eleni Zarogianni et al.
NEUROIMAGE-CLINICAL (2013)
Five Years of GWAS Discovery
Peter M. Visscher et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
Jeffrey L. Anderson et al.
CIRCULATION (2012)
Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Daniel I. Chasman et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2012)
Beyond Diagnostic Accuracy: The Clinical Utility of Diagnostic Tests
Patrick M. M. Bossuyt et al.
CLINICAL CHEMISTRY (2012)
Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record
J. T. Delaney et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
Harshal A. Deshmukh et al.
JOURNAL OF LIPID RESEARCH (2012)
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
Jason D. Roberts et al.
LANCET (2012)
What makes UK Biobank special?
Rory Collins
LANCET (2012)
The role of ATM in response to metformin treatment and activation of AMPK reply
Kaixin Zhou et al.
NATURE GENETICS (2012)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Biomarkers and surrogate endpoints in clinical trials
Thomas R. Fleming et al.
STATISTICS IN MEDICINE (2012)
Current Practices for DNA Sample Collection and Storage in the Pharmaceutical Industry, and Potential Areas for Harmonization: Perspective of the I-PWG
M. A. Franc et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The Emerging Role of Electronic Medical Records in Pharmacogenomics
R. A. Wilke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Jesus Garcia-Donas et al.
LANCET ONCOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
Kaixin Zhou et al.
NATURE GENETICS (2011)
BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
Anthony C. Faber et al.
CANCER DISCOVERY (2011)
Fine Mapping of Five Loci Associated with Low-Density Lipoprotein Cholesterol Detects Variants That Double the Explained Heritability
Serena Sanna et al.
PLOS GENETICS (2011)
Molecular Target Class Is Predictive of In vitro Response Profile
Joel Greshock et al.
CANCER RESEARCH (2010)
Sort1, Encoded by the Cardiovascular Risk Locus 1p13.3, Is a Regulator of Hepatic Lipoprotein Export
Mads Kjolby et al.
CELL METABOLISM (2010)
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
Kiran Musunuru et al.
NATURE (2010)
Hundreds of variants clustered in genomic loci and biological pathways affect human height
Hana Lango Allen et al.
NATURE (2010)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Bayesian statistical methods for genetic association studies
Matthew Stephens et al.
NATURE REVIEWS GENETICS (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
Fumihiko Takeuchi et al.
PLOS GENETICS (2009)
Community Consultation and Communication for a Population-Based DNA Biobank: The Marshfield Clinic Personalized Medicine Research Project
Catherine A. McCarty et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2008)
Development of a large-scale de-identified DNA biobank to enable personalized medicine
D. M. Roden et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
Mark I. McCarthy et al.
NATURE REVIEWS GENETICS (2008)
HLA-B*5701 screening for hypersensitivity to abacavir
Simon Mallal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pharmacogenetics of apolipoprtein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease
Tuomo Nieminen et al.
PHARMACOGENOMICS (2008)
Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes
Rinki Murphy et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations
Meena Rafiq et al.
DIABETES CARE (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Ewan R. Pearson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Why most published research findings are false
JPA Ioannidis
PLOS MEDICINE (2005)
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
M Wadelius et al.
PHARMACOGENOMICS JOURNAL (2005)
Genetic cause of hyperglycaemia and response to treatment in diabetes
ER Pearson et al.
LANCET (2003)
Replication validity of genetic association studies
JPA Ioannidis et al.
NATURE GENETICS (2001)
High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence
B Rannala et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
ADME/PK as part of a rational approach to drug discovery
PJ Eddershaw et al.
DRUG DISCOVERY TODAY (2000)
Testing drug response in the presence of genetic information: sampling issues for clinical trials
LR Cardon et al.
PHARMACOGENETICS (2000)
分享论文
